CAM
CYTK icon

Cresset Asset Management’s Cytokinetics CYTK Stock Holding History

Cresset Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-193
Closed -$2K – 755
2019
Q1 		$2K Hold
193
– – ﹤0.01% 1626
2018
Q4 		$1K Buy
+193
New +$1.42K ﹤0.01% 1477

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Cresset Asset Management's CYTK Position: Q2 2019 in Review

Cresset Asset Management sold out of Cytokinetics (CYTK) in Q2 2019, closing a stake of 193 shares — an estimated $2K sold.

Cresset Asset Management first reported a position in CYTK in Q4 2018 and held it in 2 quarters. The position peaked at $2K in Q1 2019. 134 funds tracked by Wall St. Rank hold CYTK as of Q2 2019.

  • Cresset Asset Management reported no remaining Cytokinetics position as of Q2 2019 after selling out during the quarter.
  • Cresset Asset Management sold 193 Cytokinetics shares in Q2 2019, an estimated $2K.
  • Cresset Asset Management first reported a position in Cytokinetics in Q4 2018 and held it in 2 quarters.
  • Cresset Asset Management's Cytokinetics position peaked at $2K in Q1 2019.
  • 134 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2019.

Based on Cresset Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.